Eli Lilly’s Sterling Results Highlight Rival Novo Nordisk’s Fading Fortunes

Eli Lilly dealt a George Foreman-worthy blow in its ongoing heavyweight title bout against Novo Nordisk for weight-loss drugmaker supremacy. The Indianapolis-based pharmaceutical company posted what many analysts pointed to as the strongest earnings of the season on Wednesday. Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring, leaving its weight loss rival’s prospects looking like wishful shrinking. SUBSCRIBE:  Receive more of our free The Daily Upside newsletter. READ ALSO: Chipotle ...